精密恶性瘤治疗的降解尾驱动CELMoD抗体结合物的合理工程
Yu Guo1, Yi Song1, Hanlin Wang2,3
1Institute of Drug Discovery and Design, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Acta pharmaceutica Sinica. B
|January 1, 2026
概括
新的降解剂抗体结合物 (DAC) 显示出强大的抗癌活性. 研究人员开发了一种新的cereblon E3酶调节器 (CELMoD) 有效载荷,I034,在治疗多发性骨髓瘤等血液恶性瘤方面表现出卓越的疗效和安全性.
科学领域:
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 降解剂抗体结合物 (DAC) 是血液恶性瘤的有前途的治疗策略.
- 目前缺乏DAC的合理设计框架.
- 塞雷布隆E3结合酶调节器 (CELMoDs) 为新型结合物开发提供了潜力.
研究的目的:
- 建立抗体降解剂兼容性和结合性的设计策略.
- 为了确定用于DAC构建的新型CELMoD有效载荷.
- 评估新型DAC在血液性恶性瘤中的疗效和安全性.
主要方法:
- 对抗体降解剂兼容性的系统性探索.
- 开发一个模块化图书馆用于新基板选.
- 一个新的CELMoD有效载荷的识别和结合 (I034).
- 在体外和体内对基于I034的DACs与奥里斯塔丁合物相比进行了评估.
主要成果:
- 确定了I034,一种具有皮科莫尔降解活性和抗增殖作用的CELMOD有效载荷.
- 基于I034构建的DAC显示出比auristatin合物更高的疗效和安全性.
- 在体内通过低剂量的CD38向Dara-VA-I034实现了完全的瘤根除.
- 揭示了CD38合体的明显的正反调节,强调有效载荷-抗原兼容性.
结论:
- 开发的方法为发现DAC的CELMoD有效载荷提供了一个框架.
- 基于I034的DAC显示出治疗多发性骨髓瘤和其他血液恶性瘤的巨大潜力.
- 有效载荷-抗原兼容性对于优化DAC的有效性和安全性至关重要.
关键词:
抗体药物结合物 抗体药物结合物塞雷布隆E3酶调节器降解剂抗体结合物血液的恶性瘤.免疫调节药物是一种免疫调节药物.分子粘合剂是一种分子粘合剂.多发性骨髓瘤是一种多发性骨髓瘤.有针对性的蛋白质降解降解.更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
8.0K
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
8.1K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K